EA200802132A1 - Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов - Google Patents

Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов

Info

Publication number
EA200802132A1
EA200802132A1 EA200802132A EA200802132A EA200802132A1 EA 200802132 A1 EA200802132 A1 EA 200802132A1 EA 200802132 A EA200802132 A EA 200802132A EA 200802132 A EA200802132 A EA 200802132A EA 200802132 A1 EA200802132 A1 EA 200802132A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
compositions
pain
active agent
methods
Prior art date
Application number
EA200802132A
Other languages
English (en)
Inventor
Йохен Антель
Питер-Колин Грегори
Йосефус Хубертус Мария Ланге
Михаэль Фирнгес
Дания Райхе
Original Assignee
Зольвай Фармасьютиклз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зольвай Фармасьютиклз Гмбх filed Critical Зольвай Фармасьютиклз Гмбх
Publication of EA200802132A1 publication Critical patent/EA200802132A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Фармацевтическая композиция, включающая фармацевтически эффективные количества каждого из следующих компонентов: а) по крайней мере одного модулятора каналов Кв качестве первого активного агента и б) по крайней мере одного модулятора CBв качестве второго активного агента. Изобретение относится также к применению таких композиций и к способам профилактики, лечения, замедления развития, замедления начала и/или подавления ряда заболеваний, включающих ожирение, сахарный диабет, метаболический синдром, синдром X, инсулиному, семейную гиперинсулиновую гипогликемию, облысение мужского типа, повышенную реактивность мышцы-сжимателя, астму, нейрозащиту, эпилепсию, аналгезию, кардиопротекцию, стенокардию, кардиоплегию, аритмию, спазм коронарных сосудов, заболевание периферических сосудов, спазм черепно-мозговых сосудов, регуляцию аппетита, нейродегенерацию, боль, включая нейропатическую боль и хроническую боль, и импотенцию у млекопитающих и человека, и способ заключается во введении таких композиций субъектам, нуждающимся в таком лечении. Изобретение относится также к способам получения таких композиций.
EA200802132A 2006-04-27 2007-04-20 Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов EA200802132A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113188 2006-04-27
PCT/EP2007/053914 WO2007125048A1 (en) 2006-04-27 2007-04-20 Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators

Publications (1)

Publication Number Publication Date
EA200802132A1 true EA200802132A1 (ru) 2009-06-30

Family

ID=37022868

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802132A EA200802132A1 (ru) 2006-04-27 2007-04-20 Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов

Country Status (13)

Country Link
EP (1) EP2026798A1 (ru)
JP (1) JP2009534439A (ru)
KR (1) KR20090007606A (ru)
CN (1) CN101431998A (ru)
AR (1) AR060625A1 (ru)
AU (1) AU2007245733A1 (ru)
BR (1) BRPI0711064A2 (ru)
CA (1) CA2650566A1 (ru)
EA (1) EA200802132A1 (ru)
IL (1) IL194942A0 (ru)
MX (1) MX2008013678A (ru)
TW (1) TW200808785A (ru)
WO (1) WO2007125048A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269869A (ja) * 2008-05-09 2009-11-19 Japan Health Science Foundation カンナビノイド受容体アゴニストの新規用途
WO2013140342A1 (en) * 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
WO2014208939A1 (en) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
CN106138053B (zh) * 2015-04-28 2019-04-09 上海市同济医院 一种化合物在制备治疗帕金森病的药物中的应用
US20190060300A1 (en) * 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2020123250A1 (en) * 2018-12-11 2020-06-18 John Heaney Cannabinoid derivatives and methods for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
UA74367C2 (ru) * 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПРОИЗВОДНЫЕ 4,5-ДИГИДРО-1Н-ПИРАЗОЛА, КОТОРЫЕ ПРОЯВЛЯЮТ АНТАГОНИСТИЧЕСКУЮ АКТИВНОСТЬ ОТНОСИТЕЛЬНО СВ<sub>1, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
ES2229132T3 (es) * 2001-03-22 2005-04-16 Solvay Pharmaceuticals B.V. Derivados de 4,5-dihidro-1h-pirazol que tienen actividad como antagonistas de cb1.
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
AU2005298692A1 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions

Also Published As

Publication number Publication date
BRPI0711064A2 (pt) 2011-08-23
MX2008013678A (es) 2008-11-04
IL194942A0 (en) 2009-08-03
WO2007125048A1 (en) 2007-11-08
CN101431998A (zh) 2009-05-13
EP2026798A1 (en) 2009-02-25
JP2009534439A (ja) 2009-09-24
CA2650566A1 (en) 2007-11-08
TW200808785A (en) 2008-02-16
AR060625A1 (es) 2008-07-02
KR20090007606A (ko) 2009-01-19
AU2007245733A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
EA200802132A1 (ru) Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
IN2015DN01132A (ru)
BRPI0514253A (pt) terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
WO2009044392A3 (en) Novel sirna structures
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
TW200728289A (en) Non-basic melanin concentrating hormone receptor-1 antagonists
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
WO2007092416A3 (en) Melanin concentrating hormone receptor-1 antagonists
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
NZ602833A (en) Oral formulations of cytidine analogs and methods of use thereof
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
Wilfong et al. Zonisamide for absence seizures
WO2008064107A3 (en) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
WO2006069276A3 (en) TRICYCLIC ō-OPIOID MODULATORS
JP2012530779A5 (ru)
CL2009000135A1 (es) Compuestos derivados de 1,4-benzodiazepinas sustituidas, inhibidores de dipeptidilpeptidasa iv (dpp-iv); composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades tales como diabetes tipo 2, cataratas, glaucoma, hipertrofia prostatica benigna, cancer, entre otras; compuestos intermediarios.
MX2009006768A (es) Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
WO2006083780A3 (en) Glucuronidated nebivolol
WO2010053861A3 (en) Biologically active amides
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases